Greenberg Traurig's David J. Dykeman Presents at ACI's Summit on Life Sciences IP Due Diligence
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: PR Web
BOSTON (PRWEB) November 13, 2019 David J. Dykeman, patent attorney and co-chair of Greenberg Traurig, LLP's global Life Sciences & Medical Technology Group and Boston Intellectual Property & Technology (IP) Group, will present at the American Conference Institute's (ACI) 3rd Annual Summit on Life Sciences IP Due Diligence, Nov. 14-15, 2019 in Boston, MA.From 10:45 a.m. – 12:00 p.m. on Nov. 14, Dykeman will moderate the panel, "Avoiding Missteps During the Chain of Title Review: Understanding Ownership Rules," which will address patent ownership questions related to the valuation of proprietary life sciences technology. Specific topics include: Who is the true owner of the patents? Have the patents been maintained in force and the patent applications in good standing? Have any prior investors or creditors encumbered the IP by imposing liens? Has there been a valid and inclusive assignment of patents to the licensor?Panelists include: Jeffrey N. Myers, Vice President & Assistant Ge
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks [Yahoo! Finance]Yahoo! Finance
- Pfizer's First Gene Therapy Gets Approval for Clotting Disorder [BNN Bloomberg (Canada)]BNN Bloomberg
- UPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder [Yahoo! Finance]Yahoo! Finance
- Antibody-Drug Conjugates (ADC) Industry Overview 2024: Market to Exceed $40 Billion by 2029, Driven by Daiichi Sankyo's Enhertu, Roche's Kadcyla, Astellas Pharma, Pfizer's Padcev, & Gilead's Trodelvy [Yahoo! Finance]Yahoo! Finance
- FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder [CNBC]CNBC
PFE
Earnings
- 1/30/24 - Beat
PFE
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form PX14A6G
- PFE's page on the SEC website